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Abstract
Objective: Nightmares are relatively common in patients experiencing psychosis but rarely assessed or treated. Nightmares
may maintain persecutory delusions by portraying fears in sensory-rich detail. We tested the potential benefits of imagery-
focused cognitive behavioural therapy (CBT) for nightmares on nightmare severity and persecutory delusions.
Method: This assessor-blind parallel-group pilot trial randomized 24 participants with nightmares and persecutory delusions
to receive CBT for nightmares delivered over 4 weeks in addition to treatment as usual (TAU) or TAU alone. Assessments
were at 0, 4 (end of treatment), and 8 weeks (follow-up). Feasibility outcomes assessed therapy uptake, techniques used,
satisfaction, and attrition. The primary efficacy outcome assessed nightmare severity at week 4. Analyses were intention to
treat, estimating treatment effect with 95% confidence intervals (CIs).
Results: All participants offered CBT completed therapy (mean [SD], 4.8 [0.6] sessions) with high satisfaction, and 20 (83%)
participants completed all assessments. Compared with TAU, CBT led to large improvements in nightmares (adjusted mean
difference ¼ 7.0; 95% CI, –12.6 to –1.3; d ¼ –1.1) and insomnia (6.3; 95% CI, 2.6 to 10.0; d ¼ 1.4) at week 4. Gains were
maintained at follow-up. Suicidal ideation was not exacerbated by CBT but remained stable to follow-up, compared with TAU,
which reduced at follow-up (6.8; 95% CI, 0.3 to 3.3; d ¼ 0.7). CBT led to reductions in paranoia (–20.8; 95% CI, –43.2 to 1.7; d
¼ –0.6), although CIs were wide. Three serious adverse events were deemed unrelated to participation (CBT¼ 2, TAU¼ 1).
Conclusions: CBT for nightmares is feasible and may be efficacious for treating nightmares and comorbid insomnia for
patients with persecutory delusions. It shows promise on paranoia but potentially not on suicidal ideation.
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Abre´ge´
Objectif : Les cauchemars sont relativement communs chez les patients souffrant de psychose, mais ils sont rarement e´value´s
ou traite´s. Les cauchemars peuvent nourrir les de´lires de perse´cution en incarnant les peurs par des de´tails sensoriels
abondants. Nous avons teste´ les be´ne´fices potentiels de la the´rapie cognitivo-comportementale (TCC) axe´e sur l’imagerie
pour les cauchemars relativement a` la gravite´ des cauchemars et aux de´lires de perse´cution.
Me´thode : Cet essai pilote a` l’insu de l’e´valuateur et a` groupe paralle`le a randomise´ 24 participants ayant des cauchemars et
des de´lires de perse´cution pour qu’ils rec¸oivent une TCC pour cauchemars administre´e durant 4 semaines en plus du trai-
tement habituel (TH) ou le TH seulement. Les e´valuations ont eu lieu a` 0 semaine, 4 semaines (fin du traitement) et au suivi de
8 semaines. Les re´sultats de faisabilite´ e´valuaient la participation a` la the´rapie, les techniques utilise´es, la satisfaction et
l’attrition. Le principal re´sultat de l’efficacite´ e´valuait la gravite´ des cauchemars a` la 4e semaine. Les analyses portaient sur
l’intention de traiter, estimant l’effet du traitement avec des intervalles de confiance (IC) a` 95%.
Re´sultats : Tous les participants ayant eu la TCC comple`te (moyenne ¼ 4,8 se´ances, ET ¼ 0,6) ont exprime´ une satisfaction
e´leve´e, et 20 (83%) participants ont re´pondu a` toutes les e´valuations. Comparativement au TH, la TCC entraıˆnait de grandes
ame´liorations des cauchemars (diffe´rence moyenne ajuste´e ¼ 7,0; IC a` 95% –12,6 a` –1,3, d ¼ –1,1) et de l’insomnie (6,3; IC a`
95% 2,6 a` 10,0, d ¼ 1,4) a` la 4e semaine. Les gains se maintenaient au suivi. L’ide´ation suicidaire n’e´tait pas exacerbe´e par la
TCC mais demeurait stable au suivi, comparativement au TH ou` elle e´tait re´duite au suivi (6,8; IC a` 95% 0,3 a` 3,3, d ¼ 0,7). La
TCC entraıˆnait des re´ductions de la paranoı¨a (–20.8; IC a` 95% –43.2 a` 1,7, d¼ –0,6), meˆme si les IC e´taient larges. Trois effets
inde´sirables se´rieux e´taient juge´s sans relation a` la participation (TCC ¼ 2, TH ¼ 1).
Conclusions : La TCC pour les cauchemars est faisable et peut traiter efficacement les cauchemars et l’insomnie comorbide
chez les patients souffrant de de´lire de perse´cution. Elle est prometteuse pour la paranoı¨a, mais peut-eˆtre pas pour l’ide´ation
suicidaire.
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Nightmares depict vivid and highly distressing mental ima-
gery that interrupts restorative sleep. Studies have reported
prevalence rates of problematic nightmares ranging between
9% and 55%1-3 in patients experiencing psychosis, compared
with 2% to 8% of the general population.4 Yet nightmares
are almost never assessed or treated. Nightmares may both
directly and indirectly maintain persecutory beliefs. The
direct route is that they portray paranoid fears in rich sensory
detail (e.g., the patient experiences being attacked), eliciting
a similar neural response as perception of real events.5,6
These nightmares are therefore described as seeming real,
leaving the patient acutely distressed on waking, which in
turn reinforces the fear. In the general population, the con-
tent of nightmares most commonly involves imminent phys-
ical danger,4 and the most common emotion is fear.7 This
fear might be heightened in a group with persecutory delu-
sions. The indirect route is that nightmares interrupt sleep,
triggering negative affect, which is known to exacerbate
psychotic experiences.8 This study set out to pilot a cognitive
behavioural therapy (CBT) treatment for nightmares and
assess the effect on paranoia.
Whilst nightmares are associated with a range of negative
psychiatric outcomes,9 there is a particularly strong associa-
tion with suicidal ideation. Longitudinal studies in samples
without psychosis show that frequent nightmares are associ-
ated with 8 times greater odds of later suicidal ideation,10
suicide attempts,11 and 57% greater risk of death by suicide.12
In a sample with schizophrenia, nightmares were not an indi-
vidual predictor of suicide attempts but, in conjunction with
insomnia, led to an 11-fold increase in risk of a suicide
attempt.1 Whether nightmares are an epiphenomenon or cau-
sally related to suicidal ideation is yet to be established. If a
causal relationship holds, one would predict a reduction in
suicidal ideation either concomitant with a reduction in night-
mares or at later follow-up. To our knowledge, only one pre-
vious pilot randomized controlled trial (RCT) assessed the
effect on suicidal ideation of treating nightmares.13 The pra-
zosin treatment unexpectedly increased nightmare severity,
and confidence intervals (CIs) for suicidal ideation were in
the range of an increasing or decreasing effect. Further
research is clearly warranted to elucidate whether nightmares
cause or exacerbate suicidal ideation.
The current evaluation was a pilot RCT testing brief CBT
for nightmares, compared with treatment as usual (TAU) for
patients with persecutory delusions. The primary aims were to
1) assess feasibility and acceptability of the intervention and
attrition across the follow-up period and 2) gain initial effi-
cacy data for the impact of the CBT for nightmares interven-
tion on overall nightmare severity (the primary efficacy
outcome). Piloting and feasibility assessment were therefore
integrated within this 1 trial.14 The most established technique
for treating nightmares is imagery rescripting (IR).15-17 It is
recommended in best practice guidelines15 and leads to mod-
erate reductions in nightmare frequency compared with con-
trols. IR is a form of imagery-based cognitive therapy in
which the patient directly transforms his or her mental images
related to distress, for example, by changing the outcome.18,19
Based on our learnings from a case series, IR was the core
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treatment technique,20 supplemented with CBT techniques
targeting novel potential causal factors for nightmares21
(e.g., reducing worry and oversleeping). The key efficacy
hypothesis was that CBT for nightmares in addition to TAU
would reduce nightmare severity compared with TAU.
Materials and Methods
Participants
Twenty-four participants were recruited from Oxford Health
National Health Service (NHS) Foundation Trust (n ¼ 22)
and Central and North West London NHS Foundation Trust
(n ¼ 2). All were referred by their secondary mental health
care coordinator or psychiatrist. The inclusion criteria were
1) experiencing a current chronic problem with distressing
nightmares (1 nightmare per week, which was at least mod-
erately distressing, 4 out of 7 on a Likert scale, and experi-
enced for 3 months), 2) a clinical diagnosis of nonaffective
psychosis (schizophrenia, schizoaffective disorder, delu-
sional disorder, or psychosis not otherwise specified), 3)
reporting a current persecutory delusion meeting the criteria
defined by Freeman and Garety22 and a score of 33 or above
on part A or B of the Green et al.23 Paranoid Thoughts Scale,
4) aged 18 to 65 years, and 5) on stable medication (both
drug and dose) for at least 4 weeks and no planned medica-
tion changes at the point of screening. The exclusion criteria
were 1) nightmares that were considered a side effect of
medication by the treating psychiatrist; 2) currently receiv-
ing CBT or due to commence during the trial period; 3) high
risk of sleep apnea indicated by a score of 5 on the STOP-
BANG questionnaire,24,25 with no history of having a full
assessment and/or treatment (if the participant was receiving
optimal treatment for apnoea, or further NHS assessment
resulted in no diagnosis, he or she was invited to take part);
4) a primary diagnosis of personality disorder, alcohol or
substance dependency, organic syndrome, or learning dis-
ability; or 5) a command of spoken English inadequate for
completing questionnaire measures and CBT.
Design
This was a parallel-group pilot RCT testing brief CBT for
nightmares in addition to TAU versus TAU. All participants
in the TAU group were offered the full CBT course after
their 8-week assessment. Participants were randomized
using simple randomization with a ratio of 1:1. The rando-
mization schedule was generated using www.randomisa-
tion.com, with randomly varying block sizes. A person
independent from the study team generated the allocation
sequence and placed each allocation into an opaque sealed
envelope prior to recruitment starting.
Two graduate psychologists (SR, KT) took informed con-
sent and completed trial assessments at weeks 0 (baseline), 4
(end of therapy), and 8 (follow-up). A clinical psychologist
(BS) informed the participants and their NHS care team of
the allocation outcome after completion of the baseline
assessment. Research assessors remained blind to allocation
(single-blind study). Steps to avoid revealing the allocation
status included the assessors not accessing participants’
medical records following randomization, the trial team
reminding the participants and their NHS care team not to
reveal allocation to the assessor, and the psychologist con-
cealing the diary and whereabouts from the assessors.
Where a blind was broken for the main assessor, a second
blind assessor completed that participant’s assessments and
rated the time budget measure. This occurred for 1 partici-
pant at the week 4 assessment and two further participants at
week 8 (all in the CBT group).
The study received NHS ethical approval (15/SC/0502)
and was preregistered (ISRCTN12668007). No changes
were made to methods after commencement of the trial.
Interventions
CBT for nightmares was administered by one clinical psy-
chologist (BS) with supervision from a consultant clinical
psychologist (DF) and occasional specialist input regarding
IR (EH, AG). Therapy sessions lasted around 1 hour and
took place over a 4-week window. Workbook-style manuals
written by BS, EH, and DF were shared between the parti-
cipant and therapist to increase adherence to the protocol.
These were used flexibly depending on patient preference.
The first session began with psychoeducation about night-
mares, sharing patient accounts, and key maintenance fac-
tors were identified through a nightmare-specific
assessment. IR was the key technique and offered to all
participants. In this imagery-focussed cognitive therapy
approach, participants worked to change the outcome of
their nightmare (as if rescripting the end of a film) to create
a more benign meaning. For example, if the distressing
meaning is that “no one is helping me” to escape my
attacker, the patient may change the ending such that he or
she experiences someone helping and caring for him or her.
This change of ending is planned verbally first, and then
critically, details are elicited in sensory modalities (imagi-
nation).26 A guided imagery recording and written summary
were created for each participant to aid imaginary rehearsal
between sessions. Subsequent techniques were chosen based
on the formulation. These could have included 1) reducing
presleep hyperarousal and negative thought content (relaxa-
tion, limiting worry and voices), 2) reducing fear of night-
mares by increasing coping skills (grounding techniques,
writing a compassionate message from the participant’s day-
time self), 3) reducing preoccupation related to the night-
mare (interrupting thoughts in bed by getting up and winding
down in a different room), and 4) stabilizing rapid eye move-
ment sleep across nights (reducing oversleeping or alcohol
use and increasing physical activity). Therapy ended with
relapse prevention work.
All participants continued with their NHS health care.
This typically included antipsychotic medication, regular
contact with a care coordinator, and medical reviews. When
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there were significant concerns regarding suicidal ideation,
often elicited through trial assessments, NHS teams referred
the participant for more intensive “step-up support,” typi-
cally involving daily contact until the acute risk resolved.
Feasibility and Acceptability Outcomes
A therapy log recorded CBT techniques delivered and number
of sessions used. An independent graduate psychologist (nei-
ther the assessor nor the therapist) asked each participant in
the treatment group, “Overall, how satisfied were you with the
therapy you received?” Responses were recorded using a
visual analog scale from 0 (not at all satisfied) to 10 (very
satisfied). The number who completed the follow-up assess-
ments was recorded, with reasons for dropout where available.
Primary Efficacy Outcome Measure
The Disturbing Dream and Nightmare Severity Index
(DDNSI)27 is a 5-item self-report scale assessing nightmare
severity. Questions relate to nights per week with night-
mares, nightmare frequency, awakenings, severity of night-
mare problem, and the intensity of nightmares. The total
score ranges from 0 to 37, with higher scores indicating a
more severe problem. The internal consistency of the scale in
a large sample of over 3000 students was very good (a ¼
0.91).28
Secondary Efficacy Outcomes
Other sleep outcome measures included the Sleep Condition
Indicator (SCI),29 an 8-item self-report measure of insomnia
(total score range 0-32). Higher scores indicate better sleep.
The Pittsburgh Sleep Quality Index (PSQI)30 assessed self-
reported sleep quality. The total score ranges from 0 to 21
(worse sleep).
Affective symptoms were measured by the Depression,
Anxiety and Stress Scale, 21-item version (DASS-21).31
Twenty-one items are rated from 0 to 4 and are totalled to
create 3 subscales, ranging from 0 to 21 (high).
The Green et al.23 Paranoid Thoughts Scale (GPTS)
assessed paranoia via 32 self-report items. Response options
range from 1 (not at all) to 5 (totally). The total score ranges
from 32 to 160 (high). The Cardiff Anomalous Perceptions
Scale (CAPS)32 assessed 32 anomalous experiences via self-
report. The total number of experiences endorsed (0-32) is
reported.
Other psychiatric symptoms were assessed using the Beck
Suicide Scale (BSS),33 a 21-item self-report measure of sui-
cidal ideation. Higher scores indicate increased suicidal
ideation. The Brief Dissociative Experiences Scale (DES-
B)34 assessed dissociative experiences. An average score
(ranging from 0 to 4 ¼ extreme) is calculated by dividing
the total score by 8 items.
Broader well-being measures included the Warwick-
Edinburgh Mental Wellbeing Scale (WEMWBS).35
Fourteen self-report items are rated from 1 to 5. These are
totalled to create a score ranging from 14 to 70 (high). The
Time Budget Questionnaire36 assessed activity levels, with
scores ranging from 0 to 112 (high activity).
Alternative measures of nightmares included the Oxford
Nightmare Severity Scale. This is a new measure of night-
mare severity assessed over a 2-week time frame. Three
filter questions assess nightmare frequency. If a participant
endorses experiencing at least one nightmare, 3 subscales are
completed. Each subscale includes 15 items that assess 1)
nightmare-related distress, 2) preoccupation, and 3) impair-
ment. Items are rated from 0 (not at all) to 4 (very much).
Subscale scores range from 0 to 60. All 45 items are summed
to create a total severity score (range, 0-180). Higher scores
indicate greater severity.
A prospective nightmare log was kept by participants,
completed each morning using pen and paper over a 7-day
period. They assessed 1) the number of nightmares experi-
enced, 2) a distress rating for each (1 ¼ not at all distressing,
10 ¼ extremely distressing), 3) the number of awakenings
due to nightmares, and 4) sleep quality (0 ¼ very poor, 4 ¼
very good).
Medication Use
The defined daily dose (DDD)37 was used to convert anti-
psychotic, mood stabilizer, and anxiolytic medications into
an equivalent dose for each participant. The DDD reflects
the recommended maintenance dose (long-term therapeutic
dose) of a medication and is the gold standard measure for
comparing drug utilization. The number of pro re nata (PRN,
“taken when necessary”) medications prescribed was also
measured.
Adverse Events
Serious adverse events (SAEs) were defined as 1) deaths, 2)
suicide attempts, 3) serious violent incidents, 4) admissions
to secure units, and 5) formal complaints about the therapy.
SAEs were recorded throughout the duration of the trial, and
upon completion of the trial, medical records of all partici-
pants were systematically reviewed.
Statistical Analyses
A detailed statistical analysis plan was completed prior to
conducting the analysis. A sample size of 24 was chosen to
meet the primary objective of assessing feasibility and
acceptability, rather than statistically significant between-
group changes. A sample of 24 allowed a 95% CI of the
proportion of participants who complete follow-up to have
width of 35%, if 80% complete the follow-up.
The histograms for the residuals of all efficacy outcome
measures were visually assessed and deemed sufficiently
normal for subsequent analysis. Adjusted treatment differ-
ence and 95% CIs were estimated using a linear mixed-
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effects model, which accounts for repeated measures over
time. The baseline score of each variable was added as a
covariate in the model. Assessment point (weeks 4 and 8),
outcome of randomization, and an interaction between
assessment point and randomized group were included as
fixed effects to allow estimation of the treatment effect at
the 2 time points. Random intercepts were included to
account for repeated measurements on participants. Given
the objectives of this pilot RCT, the analysis plan did not
include reporting of p values. Instead, the treatment effect
provides initial efficacy data in preparation for a larger trial.
If the 95% CI spans 0, we can be less sure of the direction of
the true treatment difference (or if there is an effect at all).
Standardized effect sizes are reported using Cohen’s d
(adjusted mean difference between groups/pooled baseline
standard deviation). Analysis began after the final assess-
ment was complete, following intention-to-treat principles.
It was conducted by BS using SPSS for Windows (version
25)38 and validated by a trial statistician (AN).
Results
Recruitment took place between February 2016 and March
2018, with breaks for staff leave and commitment to other
trials. Twenty-four participants were randomly allocated to
CBT for nightmares in addition to TAU (n ¼ 12) or TAU (n
¼ 12). Participant flow is described in the CONSORT dia-
gram (Figure 1).
Baseline Demographic and Clinical Characteristics
The 2 groups were broadly balanced with respect to the
primary efficacy outcome (DDNSI), demographics, and
clinical characteristics (Table 1). Most participants were
white British, single, and unemployed; had a diagnosis of
schizophrenia or schizoaffective disorder; and were sup-
ported by adult mental health teams. All but one participant
(in the CBT group) fell below the SCI cutoff and therefore
had insomnia disorder. Three-quarters of participants
reported that they had attempted suicide at least once in their
lifetime (prior to participation in the study).
Medication Use
Baseline medication use is shown in Table 1. The groups
were broadly balanced with respect to antipsychotics, mood
stabilizers, and anxiolytic medication. Whilst the DDD of
antidepressant medication was at the long-term therapeutic
dose in the CBT for nightmares group, it was 2.5 times that
dose in the TAU group. There were no changes in the mean
DDD of any medication from baseline to 4 or 8 weeks.
Prescriptions of PRN medication were very low across the
groups (Suppl. Table S1).
Feasibility and Acceptability Outcomes
Sessions used. All 12 participants who were offered CBT for
nightmares completed the course (at least 4 sessions ending
in relapse prevention) within the 4-week therapy window.
Four participants received 4 sessions, 7 completed 5 ses-
sions, and 1 participant received 6 sessions (mean [SD],
4.8 [0.6]).
Key techniques delivered. The CBT techniques used in the
treatment group are shown in Table 2.
Therapy satisfaction. Eleven out of 12 participants provided a
therapy satisfaction rating to an independent assessor. The
median score was 9 out of 10 (interquartile range [IQR],
6.75-10).
Primary Efficacy Outcome
The TAU group remained stable in their nightmare severity
across time. Compared with TAU, the CBT for nightmares
had a treatment benefit on nightmare severity in the large
effect size range at weeks 4 and 8 (Table 3). The 95% CIs for
the adjusted treatment effects do not cross 0.
Secondary Efficacy Outcome
The CBT for nightmares group had a treatment benefit on
insomnia in the large effect size range at weeks 4 and 8. The
CIs do not overlap 0 (Table 3). For paranoia, sleep quality,
affective symptoms, dissociation, emotional well-being, and
additional nightmare measures by week 4 (end of therapy),
the effects were in the direction of CBT for nightmares
improving outcomes. For paranoia, sleep quality, dissocia-
tion, and additional nightmare measures, the direction of this
effect remained at follow-up (Tables 3 and 4).
For hallucinations and activity levels, there was no effect
favouring either group. The TAU group had a much higher
starting mean suicidal ideation at baseline that decreased,
whereas the suicidal ideation for the CBT group remained
relatively stable from week 0 to week 8. There was a small
effect size improvement in suicidal ideation for the TAU
group at week 4, but the CIs for the treatment effects are
wide and include zero. By week 8, recovery in suicidal idea-
tion for the TAU group resulted in a medium effect size
improvement when compared to the CBT group. CIs do not
cross zero. Post hoc exploratory analysis revealed that of the
11 participants who reported no suicidal ideation at baseline
(6 participants ¼ CBT group, 5 participants ¼ TAU group),
one participant reported new onset of suicidal ideation
within the trial period. This was a TAU group participant
at week 8 (supplementary materials).
At week 4, the effect sizes for affective symptoms and
well-being were in the direction of CBT for nightmares
improving outcomes, albeit with CIs overlapping 0. By week
8, both groups had improved on measures of depression and
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stress, but the direction of effect favoured more recovery in
the TAU group. The 95% CIs, however, overlap 0. There
was no effect for anxiety favouring either group at week 8.
Serious Adverse Events
There were 3 SAEs, all of which were suicide attempts (2 ¼
CBT for nightmares group, 1 ¼ TAU group). An adverse
event report was written, and each was assessed by the chief
investigator as unrelated to participation in the trial based on
1) the temporal relationship between trial procedures and
adverse events, 2) participant report of reasons for suicidal
ideation, and 3) reasons for suicidal ideation obtained from
medical notes. Two participants continued participation in
the trial, and 1 chose to not complete the final assessment
owing to being unwell.
Discussion
This was the first RCT to assess a brief CBT intervention
targeting nightmares specifically for patients with psychosis.
Methodological rigour was high for a pilot trial: random
allocation was used, assessments were successfully blinded,
all participants completed therapy, follow-up rates were
high, and therapy satisfaction was collected by an indepen-
dent assessor.
Figure 1. CONSORT flow diagram. CBT, cognitive behavioural therapy; TAU, treatment as usual.
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A large reduction in nightmare severity was found in the
CBT group compared with TAU. This effect size is similar
to or indeed slightly larger than other trials of IR tested in
groups without psychosis.39 This questions the common rec-
ommendation that comorbid psychosis may be a contraindi-
cation for IR. A large reduction in insomnia was also found
following CBT compared with TAU. This may be due to a
reduction in nightmare-related awakenings, reduced fear of
sleep, or sleep window stabilization. The fact that this 4-
week intervention affects insomnia as well as nightmares
is highly promising given that the 2 conditions are highly
comorbid in the psychosis population, although this of
course requires replication in an adequately powered trial.2
The trial also collected data on a new outcome in the
evaluation of the effects of the treatment of nightmares:
persecutory delusions. The intervention that focused on the
content of nightmares via IR, without any behavioural tests
of persecutory beliefs, led to moderate reductions in para-
noia at weeks 4 and 8 compared with TAU. This is consistent
with the view that nightmares may maintain the persecutory
fear, although further research in an adequately powered trial
is required to establish effect sizes more precisely. Focusing
on “dreams” rather than the persecutory belief per se allowed
an opportunity to be creative, encouraging belief flexibility
by considering alternative safe endings. Bringing the percep-
tual system online using guided imagery allowed partici-
pants to try out this new safe ending and experience the
associated sensory and emotional detail.40,41 The approach
was well received by participants, as indicated by 100%
therapy completion and high therapy satisfaction.
An unexpected finding was the recovery of suicidal idea-
tion for the TAU group compared with stable but not exa-
cerbated suicidal ideation in the CBT group. The CBT group
also showed descriptively slower recovery in depression at
week 8 compared to TAU. The sample size is clearly small,
particularly so for suicidal ideation given that only half of
Table 1. Baseline Demographics and Clinical Characteristics (N ¼
24).
CBT for Nightmares (n ¼ 12) Treatment as Usual (n ¼ 12)
Age, mean (SD), y 43 (12) 39 (13)
Sex
Female 5 (42) 5 (42)
Male 7 (58) 7 (58)
Ethnicity and citizenship
White British 10 (83) 9 (75)
Mixed/multiple ethnic groups—
White and Black African
1 (8) 0 (0)
Black Caribbean 1 (8) 0 (0)
Other 0 (0) 1 (8)
Asian/Asian British—Indian 0 (0) 1 (8)
Asian/Asian British—Pakistani 0 (0) 1 (8)
Marital status
Single 10 (83) 7 (58)
Married 2 (17) 3 (25)
Cohabiting 0 (0) 1 (8)
Divorced/separated 0 (0) 1 (8)
Employment status
Unemployed 9 (75) 10 (83)
Self-employed 0 (0) 1 (8)
Student 2 (17) 1 (8)
Retired 1 (8) 0 (0)
Diagnosis
Schizophrenia 6 (50) 3 (25)
Schizoaffective disorder 5 (42) 4 (33)
Delusional disorder 0 (0) 1 (8)
Psychosis not otherwise specified 1 (8) 4 (33)
Clinical team
Adult mental health team 10 (83) 9 (75)
Adult inpatient ward 1 (8) 0 (0)
Early intervention service 1 (8) 3 (25)
Medication use, mean (SD)
Antipsychotic DDD 1.5 (0.6) 1.5 (1.0)
Mood stabilizer DDD 0.1 (0.2) 0.1 (0.3)
Anxiolytic DDD 0.0 (0.1) 0.1 (0.3)
Antidepressant DDD 1.0 (1.3) 2.5 (1.7)
Nightmare severity (DDNSI),
mean (SD)
21.6 (6.9) 23.0 (6.4)
Number of nightmares per week
(median, IQR)
4.0 (2.8-7.5) 3.5 (3.0-8.0)
Insomnia disorder (SCI cutoff) 11 (92) 12 (100)
Current suicidal ideation (BSS >0) 6 (50) 7 (58)
Number of previous suicide
attempts
Never previously attempted
suicide
4 (33) 2 (17)
Attempted suicide once 2 (17) 3 (25)
Attempted suicide 2 or more
times
6 (50) 7 (58)
Data are n (%) unless otherwise specified.
BSS, Beck Suicide Scale; CBT, cognitive behavioural therapy; DDD, defined
daily dose of medication; DDNSI, Disturbing Dream and Nightmare Sever-
ity Index; IQR, interquartile range; SCI, sleep condition indicator.
Table 2. Cognitive Behavioural Therapy Techniques Used within
the Treatment Group.
Technique
Number of
Participants
(n ¼ 12) %
Psychoeducation 12 100.0
Relapse prevention 12 100.0
Imagery rescripting 11 91.7
Reducing presleep hyperarousal: relaxation
activities
8 66.7
Reducing fear of nightmares: compassionate
message
8 66.7
Stabilizing REM sleep: limiting sleep duration 6 50.0
Reducing presleep hyperarousal: limiting
presleep worry
5 41.7
Interrupting nightmare-related preoccupation:
15-minute rule
5 41.7
Stabilizing REM sleep: increasing positive
activity
3 25.0
Reducing fear of nightmares: grounding
techniques
3 25.0
REM, rapid eye movement.
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Table 3. Scores for Primary and Secondary Efficacy Outcome Measures.
CBT for Nightmares
(n ¼ 12), Mean (SD) n
Treatment as Usual
(n ¼ 12), Mean (SD) n
Adjusted Mean
Difference (95% CI) Effect Size (d)
Primary outcome measure
Nightmare severity (DDNSI)
Week 0 21.6 (6.9) 12 23.0 (6.4) 12
Week 4 14.2 (8.8) 12 22.6 (7.1) 11 –7.0 (–12.6 to –1.3) –1.06
Week 8 12.6 (8.6) 11 22.1 (8.2) 9 –6.7 (–12.4 to –0.9) –1.02
Secondary outcome measures
Insomnia (SCI-8 item)
Week 0 8.6 (4.5) 12 7.6 (4.6) 12
Week 4 15.2 (7.7) 12 7.4 (5.0) 10 6.3 (2.6 to 10.0) 1.40
Week 8 14.9 (6.9) 11 8.4 (6.8) 9 4.3 (0.4 to 8.1) 0.95
Sleep quality (PSQI)
Week 0 12.2 (4.4) 12 12.7 (3.5) 12
Week 4 10.2 (3.8) 12 12.5 (4.3) 10 –1.9 (–4.1 to 0.4) –0.48
Week 8 9.6 (3.9) 11 11.8 (3.8) 9 –1.7 (–4.0 to 0.6) –0.43
Depression (DASS-21)
Week 0 13.2 (5.5) 12 14.3 (5.7) 12
Week 4 10.8 (7.0) 12 13.8 (6.5) 10 –0.9 (–4.5 to 2.8) –0.15
Week 8 11.5 (5.8) 11 10.6 (5.3) 9 3.3 (–0.5 to 7.1) 0.60
Anxiety (DASS-21)
Week 0 10.8 (5.1) 12 14.5 (5.2) 12
Week 4 7.4 (5.8) 12 13.3 (5.4) 10 –2.4 (–5.0 to 0.2) –0.45
Week 8 7.6 (5.3) 11 11.0 (4.6) 9 0.4 (–2.3 to 3.1) 0.08
Stress (DASS-21)
Week 0 11.8 (4.0) 12 15.5 (3.7) 12
Week 4 9.0 (5.6) 12 15.9 (3.1) 10 –2.6 (–6.1 to 0.9) –0.61
Week 8 10.4 (6.2) 11 13.3 (5.1) 9 1.1 (–2.5 to 4.7) 0.27
Paranoia (GPTS)
Week 0 101.2 (35.7) 12 109.8 (33.9) 12
Week 4 75.3 (37.0) 12 109.0 (32.3) 10 –20.8 (–43.2 to 1.7) –0.60
Week 8 68.5 (39.4) 11 100.7 (35.5) 9 –18.5 (–41.0 to 4.0) –0.54
Hallucinations—total endorsement (CAPS total)
Week 0 17.7 (7.7) 12 18.8 (7.1) 12
Week 4 15.5 (7.7) 12 16.8 (7.3) 10 0.9 (–4.0 to 5.8) 0.12
Week 8 15.8 (7.8) 11 16.7 (10.1) 9 0.8 (–4.2 to 5.8) 0.11
Suicidal ideation (BSS)
Week 0 6.5 (8.4) 12 10.5 (10.6) 12
Week 4 5.7 (7.6) 12 5.9 (7.5) 10 2.8 (–3.5 to 9.2) 0.30
Week 8 7.2 (10.9) 11 2.7 (5.7) 9 6.8 (0.3 to 13.3) 0.71
Dissociation—average (DES-B average)
Week 0 1.7 (0.7) 12 2.1 (0.8) 12
Week 4 1.5 (0.9) 12 2.4 (0.6) 10 –0.7 (–1.4 to 0.1) –0.84
Week 8 1.2 (1.0) 11 1.9 (0.8) 9 –0.4 (–1.2 to 0.3) –0.54
Emotional well-being (WEMWBS)
Week 0 38.6 (7.5) 12 34.0 (9.7) 12
Week 4 44.5 (12.2) 12 34.2 (10.4) 10 3.8 (–4.6 to 12.2) 0.43
Week 8 44.1 (12.4) 11 41.0 (9.9) 9 –4.2 (–12.9 to 4.6) –0.47
Activity levels (time budget)
Week 0 61.9 (14.6) 12 60.1 (10.0) 11
Week 4 65.7 (18.0) 11 62.1 (9.6) 10 1.1 (–7.7 to 9.9) 0.09
Week 8 63.1 (16.1) 11 62.6 (7.8) 9 –1.7 (–10.7 to 7.3) 0.14
All analyses controlled for baseline score for that variable.
BSS, Beck Suicide Scale; CAPS, Cardiff Anomalous Perceptions Scale (higher scores indicate more severe symptoms); CBT, cognitive behavioural therapy; CI,
confidence interval; DASS-21, Depression Anxiety and Stress Scale–21-item version (higher scores indicate more severe symptoms); DDNSI, Disturbing
Dream and Nightmare Severity Index (higher scores indicate a more severe problem with nightmares); DES-B, Brief Dissociative Experiences Scale; GPTS,
Green Paranoid Thoughts Scale (higher scores indicate more severe symptoms); PSQI, Pittsburgh Sleep Quality Index (lower scores indicate better sleep
quality); SCI-8, Sleep Condition Indicator–8-item version (higher scores indicate less insomnia); WEMWBS, Warwick-Edinburgh Mental Wellbeing Scale.
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the participants scored above 0 at baseline, so this result
should be interpreted cautiously. However, possible inter-
pretations include the following: 1) incomplete remission
in the nightmares for some participants in the CBT group
may prolong hopelessness and hence maintain suicidal idea-
tion; 2) focusing on nightmare imagery in CBT may
heighten awareness of suicidal “fast-forward” imagery,
which was not the focus of the intervention but is a risk
factor for later ideation42,43; or 3) the TAU group received
the CBT intervention immediately after their 8-week assess-
ment and hence may have been more optimistic at that point.
Given that two-thirds of the sample had previously
attempted suicide and around half reported current ideation,
it is clearly an important clinical issue. Future studies should
carefully monitor it and any associated imagery.
There are clear limitations to the current trial. The pre-
determined sample size was not designed to detect signifi-
cant differences; hence, future adequately powered studies
are required to establish the efficacy of the intervention. The
TAU group had a higher dose of antidepressant medication
throughout the trial, and antidepressants have been linked
with alterations in rapid eye movement sleep. As is typical
of pilot trials, recruitment took place at one university centre
with one therapist, which limits generalizability. No assess-
ment was made of therapist adherence to CBT. The measure
of hallucinations (CAPS) included a range of hallucinatory
experiences (e.g., auditory and visual domains). A clinical
observation was that in some cases, nightmares played out
threats from voices, but the CAPS was likely not sensitive
enough to abusive voices specifically to detect any potential
change. There was no active control group, and hence it is
not possible to attribute the changes in nightmares to the
CBT specifically over and above nonspecific effects of
therapy. Whilst this is an appropriate design for a trial of
this size,44 later efficacy trials would benefit from compar-
ison with an active control (e.g., befriending).
The current results suggest that a brief, targeted CBT
intervention for nightmares using IR is feasible and may lead
to substantial improvements in nightmares and insomnia.
This therapy could be a standalone intervention or form part
of a longer piece of work targeting maintenance factors for
persecutory delusions. A larger trial is warranted to establish
efficacy data, but suicidal ideation requires careful
monitoring.
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